Clinical Trial

Mosunetuzumab for CLL MRD Clearance

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of the study drugs in this research study are: * Mosunetuzumab * BTK inhibitor: Ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-28; most recent amendment 2025-12-12.
Status change: Not Yet Recruiting → Recruiting 2025-12-12
Trial Details
NCT Number NCT07052695
Lead Sponsor Inhye Ahn
Collaborators: Genentech, Inc.
Conditions Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
Enrollment 40 participants
Start Date 2025-11-24
Primary Completion 2028-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-15